Glaucoma, a chronic progressive optic neuropathy causing irreversible vision loss, in patients undergoing PreserFlo MicroShunt implantation to lower intraocular pressure across varying disease severities. PreserFlo MicroShunt Glaucoma surgery Minimally Invasive Bleb Surgery (MIBS) Glaucoma severity Surgical outcome
Conditions
Interventions
Patients classified with Mild Glaucoma pre-operatively based on a reliable Standard Automated Perimetry (SAP) mean deviation (MD) value greater than -6.00 dB (Hodapp-Anderson-Parrish staging). For pat
Treatment,Treatment,Treatment
Mild Glaucoma,Moderate glaucoma,Severe glaucoma
Sponsors
Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 years or older with a diagnosis of glaucoma. 2. Patients with a clinical indication for PreserFlo MicroShunt implantation, either as a standalone procedure or combined with cataract surgery. 3. Patients who underwent surgery at participating hospitals or medical centers, performed by glaucoma specialists involved in this study.
Exclusion criteria
Exclusion criteria: 1. Eyes with a history of previous complicated cataract surgery. 2. Patients with ocular or systemic conditions that may affect vision or visual field testing results, such as advanced diabetic retinopathy, retinal degeneration, cerebrovascular disease, or neuromuscular disorders. 3. Patients who were unable to complete the scheduled postoperative follow-up visits.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure At 12 months post PreserFlo MicroShunt Implantation Goldmann applanation tonometer | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Field (Median Deviation (dB), Pattern Standard deviation (dB), Visual Field Index (%) Within one year after PreserFlo MicroShunt Implantation A Humphrey visual field,Best-Corrected Visual Acuity (logMAR) Within one year after PreserFlo MicroShunt Implantation Snellen chart,Number of topical antiglaucoma medications Within one year after PreserFlo MicroShunt Implantation Out-Patient Department Record,Vertical cup-to-disc ratio Within one year after PreserFlo MicroShunt Implantation Slit lamp examination,RNFL Thickness (Average, Superior, Inferior, Nasal, Temporal) Within one year after PreserFlo MicroShunt Implantation Optical Coherence Tomography Printout,Lens status (phakia/pseudophakia/Aphakia) Within one year after PreserFlo MicroShunt Implantation Out-Patient Department Record,Preserflo Surgery Method Within one year after PreserFlo MicroShunt Implantation Operative note,Complication Operative note Out-Patient Department Record/,Post operative bleb needling +/- antimetabolite Within one year after PreserFlo MicroShunt Implantation Out-Patient Department Record,Endothelial Cell Density Within one year after PreserFlo MicroShunt Implantation Specular microscopy | — |
Countries
Thailand
Contacts
Public ContactKitiya Ratanawongphaibul
Center of Excellence in Glaucoma, Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University
Outcome results
None listed